Insulin Glargine Solostar (Insulin Glargine,Hum.Rec.Anlog) Patent Expiration, LOE Window & CMS Spending

Insulin Glargine Solostar (Insulin Glargine,Hum.Rec.Anlog) by Winthrop US: Off-Patent Genericized (AB Competition), 0 AB generics, $12.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorWinthrop US
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$12.3M
2024 Medicare Part D Spend$5.3M
2024 Medicaid Spend$7.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel